<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0016-3813</journal-id>
<journal-title><![CDATA[Gaceta médica de México]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. Méd. Méx]]></abbrev-journal-title>
<issn>0016-3813</issn>
<publisher>
<publisher-name><![CDATA[Academia Nacional de Medicina de México A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0016-38132019000400369</article-id>
<article-id pub-id-type="doi">10.24875/gmm.19004674</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto económico de los inhibidores en hemofilia tipo A pediátrica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Facundo]]></surname>
<given-names><![CDATA[Araceli]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Castillejos]]></surname>
<given-names><![CDATA[Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[Yulia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gay]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[Diddier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad Social del Estado de México y Municipios Hospital Materno Infantil ]]></institution>
<addr-line><![CDATA[ Estado de México]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Zeed Pharmaceutical Solutions Operaciones Clínicas ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Tecnología e Información para la Salud  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>155</volume>
<numero>4</numero>
<fpage>369</fpage>
<lpage>376</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0016-38132019000400369&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0016-38132019000400369&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0016-38132019000400369&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Pocos estudios han evaluado el impacto económico de los inhibidores en hemofilia tipo A en México, especialmente en población pediátrica.  Objetivo: Determinar el impacto económico que conlleva el desarrollo de inhibidores en pacientes pediátricos con hemofilia tipo A.  Método: Se evaluaron de forma retrospectiva los pacientes con hemofilia tipo A atendidos en un servicio de hematología pediátrica entre diciembre de 2015 y noviembre de 2017, y se determinaron los costos directos e indirectos a partir de la presencia o ausencia de inhibidores.  Resultados: El análisis de costos de la población estudiada (n = 24) mostró que el diagnóstico, seguimiento, profilaxis, tratamiento y hospitalización de estos pacientes tuvo un costo de $6 883 187.4 anuales por paciente, de los cuales más de 95 % dependió del uso de factores hemostáticos. El costo anual por paciente en el grupo con inhibidores tuvo un costo de $5 548 765.0, en comparación con $1 334 422.4 del grupo sin inhibidores, 4.2 veces superior.  Conclusiones: Se trata del primer estudio nacional que muestra que el desarrollo de inhibidores en pacientes pediátricos con hemofilia tipo A eleva más de cuatro veces la erogación económica derivada de esta enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Few studies have assessed the economic impact of inhibitors in hemophilia A in Mexico, especially in the pediatric population.  Objective: To determine the economic impact entailed by the development of inhibitors in pediatric patients with hemophilia A.  Method: Patients with hemophilia A under the care of a pediatric hematology department between December 2015 and November 2017 were retrospectively assessed. Direct and indirect costs were determined based on the presence or absence of inhibitors.  Results: The cost analysis of the study population (n = 24) showed that diagnosis, follow-up, prophylaxis, treatment and hospitalization of these patients had an annual cost of $ 6 883 187.4 per patient, out of which more than 95 % depended on the use of hemostatic factors. Annual cost per patient in the group with inhibitors was $ 5 548 765.0 in comparison with $ 1 334 422.4 in the group without inhibitors, 4.2 times higher.  Conclusions: This is the first national study to show that the presence of inhibitors in pediatric patients with hemophilia A increases the cost of the disease more than four times.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Impacto económico]]></kwd>
<kwd lng="es"><![CDATA[Costo anual]]></kwd>
<kwd lng="es"><![CDATA[Hemofilia tipo A]]></kwd>
<kwd lng="es"><![CDATA[Inhibidores]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Economic impact]]></kwd>
<kwd lng="en"><![CDATA[Annual cost]]></kwd>
<kwd lng="en"><![CDATA[Hemophilia A]]></kwd>
<kwd lng="en"><![CDATA[Inhibitors]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gringeri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lundin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[von Mackensen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mantovani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<collab>ESPRIT Study Group</collab>
<article-title xml:lang=""><![CDATA[A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)]]></article-title>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2011</year>
<volume>9</volume>
<page-range>700-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of hemophilia in mainland China:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Southeast Asian J Trop Med Public Health]]></source>
<year>2014</year>
<volume>45</volume>
<page-range>455-66</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valentino]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Hakobyan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Enockson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Kakodkar]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Cong]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exploring the biological basis of haemophilic joint disease:experimental studies]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2012</year>
<volume>18</volume>
<page-range>310-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ljung]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gretenkort-Andersson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The current status of prophylactic replacement therapy in children and adults with haemophilia]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2015</year>
<volume>169</volume>
<page-range>777-86</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cortesi]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Scalone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mantovani]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Crea]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gringeri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune tolerance induction in patients with haemophilia a and inhibitors:effectiveness and cost analysis in an European Cohort (The ITER Study)]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>96-102</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlos-Rivera]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gasca-Pineda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Majluf-Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Chávez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Economic impact of hemophilia type A and B in Mexico]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2016</year>
<volume>152</volume>
<page-range>19-29</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[ZY]]></given-names>
</name>
<name>
<surname><![CDATA[Koerper]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Riske]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Ullman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden of illness:direct and indirect costs among persons with hemophilia A in the United States]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2015</year>
<volume>18</volume>
<page-range>457-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shrestha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eldar-Lissai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lakdawalla]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Batt]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-world resource use and costs of haemophilia A-related bleeding]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2017</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e267-75</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillón-Benavides]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
</person-group>
<source><![CDATA[Impacto económico del tratamiento de pacientes pediátricos con hemofilia tipo A en el Hospital Materno Infantil de ISSEMyM [tesis de posgrado]]]></source>
<year>2016</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Autónoma del Estado de México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gringeri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mantovani]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Scalone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mannucci]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<collab>COCIS Study Group</collab>
<article-title xml:lang=""><![CDATA[Cost of care and quality of life for patients with hemophilia complicated by inhibitors:the COCIS Study Group]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2003</year>
<volume>102</volume>
<page-range>2358-63</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brewer]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Mauser-Bunschoten]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Key]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Llinas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of hemophilia]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2013</year>
<volume>19</volume>
<page-range>e1-e47</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Secretaría de Salud</collab>
<source><![CDATA[Guía de práctica clínica. Diagnóstico y tratamiento de hemofilia en adultos]]></source>
<year>2010</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Secretaría de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernandes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of an individualized prophylaxis approach on young adults with severe hemophilia]]></article-title>
<source><![CDATA[Semin Thromb Hemost]]></source>
<year>2014</year>
<volume>40</volume>
<page-range>785-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balkaransingh]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel therapies and current clinical progress in hemophilia A]]></article-title>
<source><![CDATA[Ther Adv Hematol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>49-61</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
